Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan J Thompson

Showing results (191-200 of 200) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 200 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2018
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalban, Ralf Gold, Alan J Thompson, et al.
Neurology|August 7, 2025
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple SclerosisSarmad Al-Araji, Marcello Moccia, Ashwani Jha, et al.
The Lancet. Neurology|December 26, 2017
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaAlan J Thompson, Brenda L Banwell, Frederik Barkhof, et al.
Annals of Neurology|January 14, 2018
Deep gray matter volume loss drives disability worsening in multiple sclerosisArman Eshaghi, Ferran Prados, Wallace J Brownlee, et al.
Neurology|May 30, 2014
Defining the clinical course of multiple sclerosis: the 2013 revisionsFred D Lublin, Stephen C Reingold, Jeffrey A Cohen, et al.
Brain : a Journal of Neurology|May 10, 2018
Progression of regional grey matter atrophy in multiple sclerosisArman Eshaghi, Razvan V Marinescu, Alexandra L Young, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
The Lancet. Neurology|September 20, 2025
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 20

Showing results (191-200 of 200) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 200 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2018
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalban, Ralf Gold, Alan J Thompson, et al.
Neurology|August 7, 2025
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple SclerosisSarmad Al-Araji, Marcello Moccia, Ashwani Jha, et al.
The Lancet. Neurology|December 26, 2017
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaAlan J Thompson, Brenda L Banwell, Frederik Barkhof, et al.
Annals of Neurology|January 14, 2018
Deep gray matter volume loss drives disability worsening in multiple sclerosisArman Eshaghi, Ferran Prados, Wallace J Brownlee, et al.
Neurology|May 30, 2014
Defining the clinical course of multiple sclerosis: the 2013 revisionsFred D Lublin, Stephen C Reingold, Jeffrey A Cohen, et al.
Brain : a Journal of Neurology|May 10, 2018
Progression of regional grey matter atrophy in multiple sclerosisArman Eshaghi, Razvan V Marinescu, Alexandra L Young, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
The Lancet. Neurology|September 20, 2025
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 20